Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2
- PMID: 27178209
- DOI: 10.1016/j.bbrc.2016.05.045
Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2
Abstract
Calcium/calmodulin-dependent kinase kinase 2 (CaMKK2) has been implicated in the regulation of metabolic activity in cancer and immune cells, and affects whole-body metabolism by regulating ghrelin-signalling in the hypothalamus. This has led to efforts to develop specific CaMKK2 inhibitors, and STO-609 is the standardly used CaMKK2 inhibitor to date. We have developed a novel fluorescence-based assay by exploiting the intrinsic fluorescence properties of STO-609. Here, we report an in vitro binding constant of KD ∼17 nM between STO-609 and purified CaMKK2 or CaMKK2:Calmodulin complex. Whereas high concentrations of ATP were able to displace STO-609 from the kinase, GTP was unable to achieve this confirming the specificity of this association. Recent structural studies on the kinase domain of CaMKK2 had implicated a number of amino acids involved in the binding of STO-609. Our fluorescent assay enabled us to confirm that Phe(267) is critically important for this association since mutation of this residue to a glycine abolished the binding of STO-609. An ATP replacement assay, as well as the mutation of the 'gatekeeper' amino acid Phe(267)Gly, confirmed the specificity of the assay and once more confirmed the strong binding of STO-609 to the kinase. In further characterising the purified kinase and kinase-calmodulin complex we identified a number of phosphorylation sites some of which corroborated previously reported CaMKK2 phosphorylation and some of which, particularly in the activation segment, were novel phosphorylation events. In conclusion, the intrinsic fluorescent properties of STO-609 provide a great opportunity to utilise this drug to label the ATP-binding pocket and probe the impact of mutations and other regulatory modifications and interactions on the pocket. It is however clear that the number of phosphorylation sites on CaMKK2 will pose a challenge in studying the impact of phosphorylation on the pocket unless the field can develop approaches to control the spectrum of modifications that occur during recombinant protein expression in Escherichia coli.
Keywords: CaMKK2; Drug screening; Fluorescent probe; Kinome; Phosphorylation; STO-609.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Crystal structure of the Ca²⁺/calmodulin-dependent protein kinase kinase in complex with the inhibitor STO-609.J Biol Chem. 2011 Jun 24;286(25):22570-9. doi: 10.1074/jbc.M111.251710. Epub 2011 Apr 19. J Biol Chem. 2011. PMID: 21504895 Free PMC article.
-
Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD.Sci Rep. 2017 Sep 18;7(1):11793. doi: 10.1038/s41598-017-12139-3. Sci Rep. 2017. PMID: 28924233 Free PMC article.
-
CaMKK2 kinase domain interacts with the autoinhibitory region through the N-terminal lobe including the RP insert.Biochim Biophys Acta Gen Subj. 2018 Oct;1862(10):2304-2313. doi: 10.1016/j.bbagen.2018.07.025. Epub 2018 Jul 24. Biochim Biophys Acta Gen Subj. 2018. PMID: 30053538
-
The Ca(2+)/Calmodulin/CaMKK2 Axis: Nature's Metabolic CaMshaft.Trends Endocrinol Metab. 2016 Oct;27(10):706-718. doi: 10.1016/j.tem.2016.06.001. Epub 2016 Jul 20. Trends Endocrinol Metab. 2016. PMID: 27449752 Free PMC article. Review.
-
The role of CaMKK2 in Golgi-associated vesicle trafficking.Biochem Soc Trans. 2023 Feb 27;51(1):331-342. doi: 10.1042/BST20220833. Biochem Soc Trans. 2023. PMID: 36815702 Free PMC article. Review.
Cited by
-
Data for the co-expression and purification of human recombinant CaMKK2 in complex with calmodulin in Escherichia coli.Data Brief. 2016 Jun 29;8:733-40. doi: 10.1016/j.dib.2016.06.033. eCollection 2016 Sep. Data Brief. 2016. PMID: 27508226 Free PMC article.
-
A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma.Front Oncol. 2021 Jun 21;11:612952. doi: 10.3389/fonc.2021.612952. eCollection 2021. Front Oncol. 2021. PMID: 34235071 Free PMC article.
-
PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway.Front Immunol. 2025 Jul 17;16:1616046. doi: 10.3389/fimmu.2025.1616046. eCollection 2025. Front Immunol. 2025. PMID: 40746562 Free PMC article.
-
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.Nat Commun. 2022 Oct 29;13(1):6483. doi: 10.1038/s41467-022-34175-y. Nat Commun. 2022. PMID: 36309495 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources